The 6th annual IFPA World Psoriasis and Psoriatic Arthritis Conference (WPPAC) provided updates on news and developments in the field.
This report will focus on:
- Identification of biomarkers
- Psoriasis and Psoriatic Arthritis relationship
- Current and new therapeutic modalities
- Patient centric research
- CARE™ Program Update – Rheumatology Needs Assessment Results:
Managing patients with Inflammatory Arthritis in 2021
Identifying which patients might progress radiographically is a key area of unmet need within PsA.
- Research on biomarkers presented at WPPAC 2021 is promising but requires further investigation
Many promising new therapies will soon be approved for PsA, but how and when new agents will be funded in Canada remains an area of speculation.
- Approval and subsequent funding should provide consideration for disease subsets which may particularly benefit from
Collaboration between dermatologists and rheumatologists should be enhanced to facilitate early referral of patients requiring co-management of psoriasis and psoriatic arthritis.
Psoriasis patients should not discontinue their biologic therapy out of risk or fear of contracting COVID-19.
- Interruption of biologic therapy should be reserved for clinically unwell patients
- Treatment and monitoring strategies that minimize contact/exposure, such as the use of oral and subcutaneous options,
should be prioritized at this time